Current regimens and novel agents for mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q38224186

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current regimens and novel agents for mantle cell lymphoma.

@en

type

Item

label

Current regimens and novel agents for mantle cell lymphoma.

@en

prefLabel

Current regimens and novel agents for mantle cell lymphoma.

@en

P1476

Current regimens and novel agents for mantle cell lymphoma.

@en

P2093

Jorge Romaguera

http://www.w3.org/2001/XMLSchema#string

Michael Wang

http://www.w3.org/2001/XMLSchema#string

Yiming Chen

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

P304

3-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13000

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263518143

http://www.w3.org/2001/XMLSchema#string

P698

24974852

http://www.w3.org/2001/XMLSchema#string